Pre-transplant CMV and EBV seroprevalence in liver transplant candidates in northern Iran

Reihaneh Sadeghi Garmaroodi; Hamed Naziri; Maryam Yaseri; Masoumeh Barsoroushan; Pirooz Samidoust

doi:10.61882/jcbior.5.1.275

Authors

Reihaneh Sadeghi Garmaroodi Razi Clinical Research Development Unit , Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran
Hamed Naziri Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran http://orcid.org/0000-0001-6290-8944
Maryam Yaseri Razi Clinical Research Development Unit , Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran
Masoumeh Barsoroushan Razi Clinical Research Development Unit , Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran
Pirooz Samidoust Razi Clinical Research Development Unit , Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran http://orcid.org/0000-0002-7916-0677

DOI:

https://doi.org/10.61882/jcbior.5.1.275

Keywords:

Cytomegalovirus, Epstein-Barr virus, Liver transplantation, Transplant recipient, Transplant donor

Abstract

Viral infections, such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV), contribute to the low survival rates of liver transplant patients. This study aimed to assess the prevalence of CMV and EBV infections in patients awaiting liver transplantation. Utilizing a census sampling approach, this cross-sectional study examined all cases of viral infections from 2016 to 2021 among liver transplant patients referred to Rasht liver transplant center, the North of Iran. The diagnosis of a recent primary viral infection was established by IgM positivity. In total, 34 individuals with a mean age of 48.9±12.2 years were included in the study. Of these, 40 individuals (59.7%) were male. The prevalence of CMV IgM and IgG antibodies among liver transplant candidates was 7.5%, and 97%, respectively. Also, the prevalence of EBV IgM and IgG antibodies was 7.5%, and 97%, respectively. The average serum vitamin D level in CMV IgM-negative patients was 30.7±17.2 compared to 55.1±22.1 in CMV IgM-positive patients (p = 0.011). The prevalence of active CMV and EBV infections in liver transplant patients was found to be 7.5%. These results highlight the necessity for continuous and effective strategies to prevent infection-related complications through prompt diagnosis and treatment, which are crucial for positive liver transplant outcomes.

References

1. Moreno R, Berenguer M. Post-liver transplantation medical complications. Ann Hepatol. 2006;5(2):77-85. PMID: 16807513

2. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant. 2004;4(3):384-9. DOI: 10.1111/j.1600-6143.2004.00350.x PMID: 14961991

3. Bowden RA, Ljungman P, Snydman DR. Transplant infections. Lippincott Williams & Wilkins; 2012. URL: https://books.google.com/books/about/Transplant_Infections.html?id=O7ujw4_HRbYC

4. Murray KF, Carithers RL Jr; AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41(6):1407-32. DOI: 10.1002/hep.20704 PMID: 15880505

5. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, Merion R, Wolfe R, Turcotte J, Teperman L; UNOS/OPTN Liver Disease Severity Score, UNOS/OPTN Liver and Intestine, and UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8(9):851-8. DOI: 10.1053/jlts.2002.35927 PMID: 12200791

6. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg. 1997;3(6):628-37. DOI: 10.1002/lt.500030613 PMID: 9404965

7. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, Kim WR. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001;7(7):567-80. DOI: 10.1053/jlts.2001.25879 PMID: 11460223

8. Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005;22(11-12):1079-89. DOI: 10.1111/j.1365-2036.2005.02691.x PMID: 16305721

9. Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, Guarrera JV, Brown RS Jr, Emond JC. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant. 2008;8(12):2537-46. DOI: 10.1111/j.1600-6143.2008.02400.x PMID: 18945283

10. Alexander J, Limaye AP, Ko CW, Bronner MP, Kowdley KV. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl. 2006;12(12):1799-804. DOI: 10.1002/lt.20827 PMID: 16741903

11. Chow JK, Werner BG, Ruthazer R, Snydman DR. Increased serum iron levels and infectious complications after liver transplantation. Clin Infect Dis. 2010;51(3):e16-23. DOI: 10.1086/654802. PMID: 20578876

12. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis. 2001;3 Suppl 2:1-5. DOI: 10.1034/j.1399-3062.2001.00001.x PMID: 11926743

13. Falagas ME, Snydman DR. Recurrent cytomegalovirus disease in solid-organ transplant recipients. Transplant Proc. 1995;27(5 Suppl 1):34-7. PMID: 7482815

14. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338(24):1741-51. DOI: 10.1056/NEJM199806113382407 PMID: 9624195

15. Tolk O RR. Viral infections in organ transplantation. 1998;10(1):1060–3. URL: https://www.researchgate.net/publication/345221946

16. Zumla A. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Lancet Infect Dis. 2010;10(5):303–4. DOI: 10.1016/S1473-3099(10)70089-X

17. Borchers AT, Perez R, Kaysen G, Ansari AA, Gershwin ME. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol. 1999;7(2):75-82. DOI: 10.1016/s0966-3274(99)80023-9 PMID: 10544437

18. Schroeder R, Michelon T, Fagundes I, Bortolotto A, Lammerhirt E, Oliveira J, Santos A, Bittar A, Keitel E, Garcia V, Neumann J, Saitovitch D. Cytomegalovirus disease latent and active infection rates during the first trimester after kidney transplantation. Transplant Proc. 2004;36(4):896-8. DOI: 10.1016/j.transproceed.2004.03.085 PMID: 15194308

19. Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M, Foss A, Leivestad T, Osnes K, Fauchald P, Rollag H. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002;2(9):850-6. DOI: 10.1034/j.1600-6143.2002.20907.x PMID: 12392291

20. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant. 2000;15(5):711-4. DOI: 10.1093/ndt/15.5.711 PMID: 10809816

21. Schnitzler MA, Lowell JA, Hmiel SP, Hardinger KL, Liapis H, Ceriotti CS, Brennan DC. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol. 2003;14(3):780-5. DOI: 10.1097/01.asn.0000051599.09435.1e PMID: 12595516

22. Rostaing L, Wéclawiak H, Mengelle C, Kamar N. Viral infections after kidney transplantation. Minerva Urol Nefrol. 2011;63(1):59-71. PMID: 21336246

23. Khorvash F. Cytomegalovirus Infection in Renal Recipients in Al_Zahra Hospital of Isfahan. J Jahrom Univ Med Sci. 2007;5(3):15–21. URL: https://doaj.org/article/3777b3f9871140968ac0f103e4c93f72

24. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation. 1995;60(6):547-54. DOI: 10.1097/00007890-199509270-00005 PMID: 7570949

25. Acott PD, Lee SH, Bitter-Suermann H, Lawen JG, Crocker JF. Infection concomitant with pediatric renal allograft rejection. Transplantation. 1996;62(5):689-91. DOI: 10.1097/00007890-199609150-00026 PMID: 8830838

26. Shahinian VB, Muirhead N, Jevnikar AM, Leckie SH, Khakhar AK, Luke PP, Rizkalla KS, Hollomby DJ, House AA. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation. 2003;75(6):851-6. DOI: 10.1097/01.TP.0000055098.96022.F7 PMID: 12660514

27. Jamalidoust M, Namayandeh M, Pouladfar G, Ziyaeyan M. Post-Liver Transplant Cytomegalovirus (CMV) Reactivation, Graft, and Patient Survival Rates in Iranian Population. Jundishapur J Microbiol. 2021;14(3). DOI: 10.5812/jjm.112775

28. Fernández-García OA, García-Juárez I, Belaunzarán-Zamudio PF, Vilatoba M, Wisniowski-Yáñez A, Salomón-Ávila J, Bobadilla-Del-Valle M, Sifuentes-Osornio J, Cuellar-Rodríguez JM. Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive liver transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study. BMC Infect Dis. 2022;22(1):155. DOI: 10.1186/s12879-022-07123-w PMID: 35164684

29. Varghese J, Subramanian S, Reddy MS, Shanmugam N, Balajee G, Srinivasan V, Venkataraman J, Mohamed R. Seroprevalence of cytomegalovirus in donors & opportunistic viral infections in liver transplant recipients. Indian J Med Res. 2017;145(4):558-562. DOI: 10.4103/ijmr.IJMR_1024_14 PMID: 28862190

30. Dehghani M, kasiri K, mohamadi J hasan pour K. Prevalence of Cytomegalovirus Infection in Candidates for Pediatric Liver Transplantation at Namazi Hospital of Shiraz During 2006-2009. sjimu. 2013;21(6):125-133. URL: http://sjimu.medilam.ac.ir/article-1-1466-en.html

31. Lizaola-Mayo BC, Rodriguez EA. Cytomegalovirus infection after liver transplantation. World J Transplant. 2020;10(7):183-190. DOI: 10.5500/wjt.v10.i7.183 PMID: 32844094

32. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet. 1997;350(9093):1729-33. DOI: 10.1016/s0140-6736(97)05535-9 PMID: 9413463

33. Abdullatif H, Dhawan A, Verma A. Epidemiology and Risk Factors for Viral Infections in Pediatric Liver Transplant Recipients and Impact on Outcome. Viruses. 2023;15(5):1059. DOI: 10.3390/v15051059. PMID: 37243144

34. Halliday N, Smith C, Atkinson C, O'Beirne J, Patch D, Burroughs AK, Thorburn D, Haque T. Characteristics of Epstein-Barr viraemia in adult liver transplant patients: a retrospective cohort study. Transpl Int. 2014;27(8):838-46. DOI: 10.1111/tri.12342 PMID: 24750406

35. Rieder FJJ, Gröschel C, Kastner MT, Kosulin K, Laengle J, Zadnikar R, Marculescu R, Schneider M, Lion T, Bergmann M, Kallay E, Steininger C. Human cytomegalovirus infection downregulates vitamin-D receptor in mammalian cells. J Steroid Biochem Mol Biol. 2017;165(Pt B):356-362. DOI: 10.1016/j.jsbmb.2016.08.002 PMID: 27520300

36. Bearden A, Van Winden K, Frederick T, Kono N, Operskalski E, Pandian R, Barton L, Stek A, Kovacs A. Low maternal vitamin D is associated with increased risk of congenital and peri/postnatal transmission of Cytomegalovirus in women with HIV. PLoS One. 2020;15(2):e0228900. DOI: 10.1371/journal.pone.0228900. PMID: 32053638

37. Shirafkan H, Yazdani Charati J, Mozaffarpur SA, Khafri S, Akbari R, Oliaei F. Evaluation of Influential Factors in the Incidence Period of Cytomegalovirus after Renal Transplantation. J Babol Univ Med Sci. 2016;18(4):41–7. URL: https://jbums.org/article-1-5811-en.pdf